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Parathyroid Adenoma: is Sestamibi scintigraphy 
mandatory? 
 
Introduction: 
  Localization of parathyroid adenoma using 99mTc scintigraphy 
is  the  standard  of  care.  However,  of  late,  ultrasound  has  been 
employed to this end with increasing frequency.1, 2, 3 The employment 
of intra-operative PTH estimation (IOPTH) has further augmented the 
cure  rate  of  hyperparathyroidism  due  to  parathyroid  adenomas.4 
While ultrasound is widely available, scintigraphy is available only in 
tertiary health-care centres.   
 
With this background, a prospective study was conducted in the 
department of endocrine surgery of a tertiary care hospital to analyse 
the efficacy of surgeon-performed ultrasound (SPUS) in comparison 
to  that  of  99mTc  Sestamibi  scintigraphy  in  the  localization  of 
parathyroid adenomas. 
Patients and methods: 
  Prospective data which were recorded over the past 5 years in 
this  unit  were  retrospectively  analysed.  Consecutive  patients  with 
primary  hyperparathyroidism  were  evaluated  and  managed.  Serum 
levels  of  calcium  (Ca),  parathormone  (PTH),  alkaline  phosphatase 
(AlP) and phosphate (PO4) were estimated. Levels of calcium in 24-
hr  urine  sample  were  estimated.  Patients  with  hypercalcemia  with 
elevation of serum calcium (S.Ca) levels more than 1 mg/dl above the 
upper  limit  of  normal  range  and  elevation  of  serum  parathormone 
(S.iPTH)  above  five  times  the  upper  limit  of  normal  range  were 
included  in  the  study.  After  confirmation  of  the  diagnosis  with 
biochemical tests, they were subjected to ultrasound and scintigraphy 
for localization of the parathyroid adenoma.  Patients in whom the  
 
above criteria were not met were excluded from the study. Those who 
were included in the study were classified into 2 groups. One group 
(Group  1)  included  patients  who  underwent  both  SPUS  and 
scintigraphy, while the other group (Group 2) included patients who 
underwent  SPUS  alone.  Patients  were  deemed  to  be  cured  of  the 
disease  if  they  remained  symptom-free for a  period  of  six  months 
after  surgery,  with  maintenance  of  eucalcemia  in  the  above-said 
period.    
 
 
Results: 
A total number of 29 patients were included in the study.  The 
two groups were analysed with regards to mean age, S.Ca, S.iPTH, 
S.AlP 24-hr urinary calcium (Table 1).  
In group 1, the patients were aged between 31 and 55 yrs (40 +/- 
6.5). The mean serum calcium was 12.1 +/- 0.8 mg/dl (8.5 – 10.5). 
The mean S.iPTH was 389 +/- 45 pg/ml (15 – 65). The mean S.AlP  
 
was 298 +/- 76 IU/L. The mean 24-hr-urinary calcium was 280 +/- 
140 mg/24hrs. 
In group 2, the patients were aged between 35 and 60 yrs (44 +/- 
5.2).  ). The mean serum calcium was 12.3 +/- 0.7 mg/dl (8.5 – 10.5). 
The mean S.iPTH was 405 +/- 58 pg/ml (15 – 65). The mean S.AlP 
was 340 +/- 90 IU/L. The mean 24-hr-urinary calcium was 310 +/- 
160 mg/24hrs.  
There  was  no  significant  difference  between  the  two  groups 
with regards to these tests.  
The adenoma was localized to superior parathyroid in 6 patients 
and to the inferior parathyroid in 9 patients in group 1. In group 2, the 
adenoma was localized to the superior parathyroid in 6 patients and to 
the inferior parathyroid in 8 patients.  
There  was  no  significant  difference  between  the  two  groups 
with regards to the size of the adenoma, weight and post-operative 
levels of S.Ca (Table 2).  
2  patients  in  group  1  and  3  patients  in  group  2  developed 
Hungry bone syndrome.  
 
Discussion: 
  The success of parathyroid surgery depends upon the accuracy 
of localization of the adenoma. While ultrasound is widely available, 
scintigraphy is available only in tertiary health-care centres.  
  In the present study, there was no significant difference between 
SPUS and scintigraphy with regards to accuracy of identification of 
the adenoma. 
  Hence,  on  the  basis  of  unequivocal  biochemical  diagnosis  of 
parathyroid adenoma, SPUS is adequate for localization of adenoma 
and further management, including MIP. Scintigraphy is not a must 
for localization and non-availability of scintigraphy does not preclude 
MIP as an option for management of parathyroid adenoma.  
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